204 related articles for article (PubMed ID: 33585126)
1. Clinicopathological Features of Primary Neuroendocrine Tumors of Gastrointestinal/Pancreatobiliary Tract With Emphasis on High-Grade (Grade 3) Well-Differentiated Neuroendocrine Tumors.
Hashmi AA; Ali J; Yaqeen SR; Ahmed O; Asghar IA; Irfan M; Asif MG; Edhi MM; Hashmi S
Cureus; 2021 Jan; 13(1):e12640. PubMed ID: 33585126
[TBL] [Abstract][Full Text] [Related]
2. Clinicopathological Spectrum of Primary and Metastatic Neuroendocrine Neoplasms.
Hashmi AA; Ali J; Khan K; Ahmed O; Rehman AU; Irfan M; Haroon S; Asif MG
Cureus; 2020 Nov; 12(11):e11764. PubMed ID: 33409012
[TBL] [Abstract][Full Text] [Related]
3. Sporadic Gastric Well-Differentiated Neuroendocrine Tumors Have a Higher Ki-67 Proliferative Index.
Lee HE; Mounajjed T; Erickson LA; Wu TT
Endocr Pathol; 2016 Sep; 27(3):259-67. PubMed ID: 27306997
[TBL] [Abstract][Full Text] [Related]
4. Urinary Neuroendocrine Neoplasms Treated in the "Modern Era": A Multicenter Retrospective Review.
Le BK; McGarrah P; Paciorek A; Mohamed A; Apolo AB; Chan DL; Reidy-Lagunes D; Hauser H; Rivero JD; Whitman J; Batty K; Zhang L; Raj N; Le T; Bergsland E; Halfdanarson TR
Clin Genitourin Cancer; 2023 Jun; 21(3):403-414.e5. PubMed ID: 37031047
[TBL] [Abstract][Full Text] [Related]
5. Assigning site of origin in metastatic neuroendocrine neoplasms: a clinically significant application of diagnostic immunohistochemistry.
Bellizzi AM
Adv Anat Pathol; 2013 Sep; 20(5):285-314. PubMed ID: 23939147
[TBL] [Abstract][Full Text] [Related]
6. Immunoreactivity of HOXB13 in Neuroendocrine Neoplasms Is a Sensitive and Specific Marker of Rectal Well-Differentiated Neuroendocrine Tumors.
Soukup J; Manethova M; Stejskal V; Hornychova H; Cesak T; Netuka D; Ryska A; Gabalec F
Endocr Pathol; 2023 Sep; 34(3):333-341. PubMed ID: 37552455
[TBL] [Abstract][Full Text] [Related]
7. SATB2 protein expression by immunohistochemistry is a sensitive and specific marker of appendiceal and rectosigmoid well differentiated neuroendocrine tumours.
Hoskoppal D; Epstein JI; Gown AM; Arnold Egloff SA; Gordetsky JB; Shi CJ; Giannico GA
Histopathology; 2020 Mar; 76(4):550-559. PubMed ID: 31595536
[TBL] [Abstract][Full Text] [Related]
8. Recent Updates on Neuroendocrine Tumors From the Gastrointestinal and Pancreatobiliary Tracts.
Kim JY; Hong SM
Arch Pathol Lab Med; 2016 May; 140(5):437-48. PubMed ID: 27128301
[TBL] [Abstract][Full Text] [Related]
9. Paired Box 5 (PAX5) Expression in Poorly Differentiated Neuroendocrine Carcinoma of the Gastrointestinal and Pancreatobiliary Tract: Diagnostic and Potentially Therapeutic Implications.
Ainechi S; Mann SA; Lin J; Patil D; Sheehan CE; Yang Z; Zuo C; Lee H
Appl Immunohistochem Mol Morphol; 2018 Sep; 26(8):545-551. PubMed ID: 27941564
[TBL] [Abstract][Full Text] [Related]
10. Somatostatin receptor scintigraphy versus chromogranin A assay in the management of patients with neuroendocrine tumors of different types: clinical role.
Cimitan M; Buonadonna A; Cannizzaro R; Canzonieri V; Borsatti E; Ruffo R; De Apollonia L
Ann Oncol; 2003 Jul; 14(7):1135-41. PubMed ID: 12853358
[TBL] [Abstract][Full Text] [Related]
11. Mitotic count by phosphohistone H3 immunohistochemical staining predicts survival and improves interobserver reproducibility in well-differentiated neuroendocrine tumors of the pancreas.
Voss SM; Riley MP; Lokhandwala PM; Wang M; Yang Z
Am J Surg Pathol; 2015 Jan; 39(1):13-24. PubMed ID: 25353284
[TBL] [Abstract][Full Text] [Related]
12. Phosphohistone H3 and Ki-67 labeling indices in cytologic specimens from well-differentiated neuroendocrine tumors of the gastrointestinal tract and pancreas: a comparative analysis using automated image cytometry.
Fung AD; Cohen C; Kavuri S; Lawson D; Gao X; Reid MD
Acta Cytol; 2013; 57(5):501-8. PubMed ID: 24021213
[TBL] [Abstract][Full Text] [Related]
13. Molecular Profiling of Well-Differentiated Neuroendocrine Tumours: The Role of ctDNA in Real-World Practice.
Lamarca A; Frizziero M; Barriuso J; Kapacee Z; Mansoor W; McNamara MG; Hubner RA; Valle JW
Cancers (Basel); 2022 Feb; 14(4):. PubMed ID: 35205766
[No Abstract] [Full Text] [Related]
14. CDX-2 homeobox gene product expression in neuroendocrine tumors: its role as a marker of intestinal neuroendocrine tumors.
Barbareschi M; Roldo C; Zamboni G; Capelli P; Cavazza A; Macri E; Cangi MG; Chilosi M; Doglioni C
Am J Surg Pathol; 2004 Sep; 28(9):1169-76. PubMed ID: 15316316
[TBL] [Abstract][Full Text] [Related]
15. Primary renal well-differentiated neuroendocrine tumors: report of six cases with an emphasis on the Ki-67 index and mitosis.
Kim B; Kim HS; Moon KC
Diagn Pathol; 2019 Feb; 14(1):12. PubMed ID: 30732641
[TBL] [Abstract][Full Text] [Related]
16. Clinicopathological features and prognosis of gastroenteropancreatic neuroendocrine neoplasms in a Chinese population: a large, retrospective single-centre study.
Zhang M; Zhao P; Shi X; Zhao A; Zhang L; Zhou L
BMC Endocr Disord; 2017 Jul; 17(1):39. PubMed ID: 28705205
[TBL] [Abstract][Full Text] [Related]
17. Clinicopathologic study of neuroendocrine tumors of gastroenteropancreatic tract: a single institutional experience.
Uppin MS; Uppin SG; Sunil CS; Hui M; Paul TR; Bheerappa N
J Gastrointest Oncol; 2017 Feb; 8(1):139-147. PubMed ID: 28280618
[TBL] [Abstract][Full Text] [Related]
18. The high-grade (WHO G3) pancreatic neuroendocrine tumor category is morphologically and biologically heterogenous and includes both well differentiated and poorly differentiated neoplasms.
Basturk O; Yang Z; Tang LH; Hruban RH; Adsay V; McCall CM; Krasinskas AM; Jang KT; Frankel WL; Balci S; Sigel C; Klimstra DS
Am J Surg Pathol; 2015 May; 39(5):683-90. PubMed ID: 25723112
[TBL] [Abstract][Full Text] [Related]
19. Well-differentiated neuroendocrine tumors in skin: Terminology and diagnostic utility of cytokeratin 5/6 and p63.
Panse G; Cowper SE; Leffell DJ; Pulitzer M; Ko CJ
J Cutan Pathol; 2017 Jun; 44(6):557-562. PubMed ID: 28417484
[TBL] [Abstract][Full Text] [Related]
20. Regional lymph node involvement and outcomes in appendiceal neuroendocrine tumors: a SEER database analysis.
Mehrvarz Sarshekeh A; Advani S; Halperin DM; Conrad C; Shen C; Yao JC; Dasari A
Oncotarget; 2017 Nov; 8(59):99541-99551. PubMed ID: 29245922
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
